ReviewCureus2025
Strategies for Reversing Exogenous Testosterone-Induced Infertility.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exogenous testosterone use in men of peak fertility age is a particular concern, as it can lead to disruption of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in infertility. Unfortunately, this population is often unaware of the adverse events, specifically infertility, that can arise from exogenous testosterone use. Discontinuation of exogenous testosterone may result in recovery in the HPG axis with time; however, not all patients will rebound or tolerate symptoms of low testosterone in the interim. Additionally, some of these patients may have an immediate interest in conception. To date, there is a paucity of literature dealing with this growing population. This article aims to review infertility and HPG axis disruption resulting from exogenous testosterone use, examine pharmacological management, guide clinicians on how to approach these patients, and provide recommendations on when to refer to urology/andrology or endocrinology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.